#Canada #Hamilton #225Ac-SSO110 #AtomVie #Ariceum

AtomVie Global Radiopharma's Breakthrough in Cancer Treatment

On November 12, 2025, AtomVie Global Radiopharma (AtomVie), a prominent Contract Development and Manufacturing Organization (CDMO) specializing in radiopharmaceuticals, announced a significant milestone in cancer treatment. The company successfully delivered the first patient dose of 225Ac-SSO110, a groundbreaking therapeutic agent developed by Ariceum Therapeutics, designed to combat small-cell lung cancer (SCLC) and Merkel cell carcinoma (MCC) in advanced stages.

This innovative partnership highlights AtomVie’s commitment to improving patient outcomes through advanced radiopharmaceuticals. The 225Ac-SSO110, a potential first-in-class agent targeting the somatostatin type-2 receptor (SSTR2), is currently undergoing evaluation in Ariceum's Phase 1/2 clinical trial, named SANTANA-225. This trial marks a critical step in delivering much-needed treatments for cancers that have limited treatment options and poor prognoses.

Collaborating for Excellence

AtomVie utilizes its cutting-edge cGMP (current Good Manufacturing Practices) facilities and extensive technical expertise to ensure the robust and reliable production of 225Ac-SSO110. This collaboration not only ensures a consistent supply of the treatment but also upholds the uncompromising quality essential for clinical success. Bruno Paquin, AtomVie’s Managing Director, expressed excitement about the partnership, stating, "We are honored to collaborate with Ariceum to deliver the critical supply of 225Ac-SSO110 for the SANTANA-225 clinical trial. Our mission to enhance the lives of patients with high-quality radiopharmaceuticals drives our commitment to this work."

A Major Milestone Achieved

The administration of the first dose to a patient marks a pivotal achievement for Ariceum Therapeutics. Manuel Sturzbecher-Höhne, Ariceum's Chief Technology Officer, emphasized the significance of this milestone, stating, "We are proud to work with AtomVie in manufacturing 225Ac-SSO110. Their proven GMP expertise and unwavering commitment to quality give us confidence that we can effectively bring 225Ac-SSO110 through clinical development, ultimately fulfilling our mission to provide transformative therapies to patients facing these aggressive, under-treated cancers."

About the Companies

AtomVie Global Radiopharma is a world leader in the GMP manufacturing and global distribution of clinical and commercial radiopharmaceuticals. The company offers a comprehensive array of scientific, technical, regulatory, quality, and logistical services alongside specialized infrastructure for radiopharmaceutical development, from clinical trials to commercial markets. AtomVie services international clients conducting clinical trials in over 28 countries. They are also in the process of building a new state-of-the-art facility that spans 72,300 square feet, slated for completion by the end of 2025.

On the other hand, Ariceum Therapeutics is a clinical-stage oncology-focused company determined to redefine the future of treatment for patients facing aggressive and hard-to-treat cancers through targeted radiotherapies. Their leading program, 225Ac-SSO110, is a novel SSTR2 antagonist being investigated as the first maintenance radiotherapy for extensive-stage SCLC and MCC, two conditions with limited treatment options.

Additionally, Ariceum is developing ATT001, a new radiolabeled I-123 PARP inhibitor intended for subcellular precision radiotherapy against aggressive solid tumors. Headquartered in Berlin, Ariceum operates in Germany, Switzerland, Australia, the UK, and the USA, backed by eminent global life science investors including EQT Life Sciences, HealthCap, Pureos Bioventures, Andera Partners, and Earlybird Venture Capital.

Conclusion

As radiopharmaceutical advancements continue to evolve, partnerships like the one between AtomVie and Ariceum underlie the commitment to combating cancers with innovative therapies. Both companies strive to bring promising treatments to patients, significantly impacting the landscape of oncology.

For further inquiries, contact:

• - AtomVie: Tina Chainani, Business Development Manager at [email protected]
• - Ariceum: Kevin Lui, Director of Investor Relations at [email protected]